REG - GenIP PLC Tekcapital plc - Corporate Update

TekcapitalAnnouncement

15/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260115:nRSO9340Oa&default-theme=true

RNS Number : 9340O  GenIP PLC  15 January 2026

 

 

 

15 January 2026

 

GenIP Plc

("GenIP" or the "Company")

 

Corporate Update

 

Progress in Product Adoption and Client Engagement

 

GenIP Plc, an AI-powered innovation intelligence and technology
commercialisation company, reports continued operational progress during 2025,
including approximately 330% revenue growth and 150% growth in gross margin
compared with FY2024. Active clients increased by over 225%, with client
retention remaining high at approximately 90%.

 

This performance has been driven by the rollout of the Company's integrated
invention intelligence product suite and increasing adoption of its Invention
Prioritizer product. Adoption in Brazil and Saudi Arabia is generating new
client introductions and contributing to a growing pipeline of inbound
enquiries. The Company's strategy to expand its corporate client base is
progressing, with new orders secured and active discussions underway with both
corporate and academic clients. Demand from Universities and other
non-corporate clients remains robust, supported by repeat orders and ongoing
international engagement.

 

Invention Prioritizer Product Order

 

The National Nuclear Energy Commission of Brazil (CNEN) has placed an order
for the recently launched Invention Prioritizer product to assess an initial
portfolio of 20 technologies for immediate delivery, with the potential,
subject to performance and client requirements, to extend the engagement to a
further 20 technologies.

 

The Invention Prioritizer, launched in November 2024, has now been applied to
a portfolio of several hundred technologies for a leading research university
in Saudi Arabia. Following delivery of this assignment, the client has
introduced GenIP to additional academic institutions in the region,
contributing to increased inbound enquiries for this higher-margin
service.

 

Corporate Orders

 

As part of the Company's previously announced strategy to broaden its
corporate client base, GenIP has begun to secure commercial traction for its
Invention Evaluator product with corporate customers.

Initial corporate orders have been secured via the recently announced
partnership with 360 Impact Studio, alongside a direct corporate engagement
relating to AI-based computer vision and object annotation technology. Further
corporate discussions are ongoing.

 

 Academic Orders

 

Academic clients continue to demonstrate strong repeat demand for the
Invention Evaluator products with new demand supported by both returning and
newly engaged institutions:

●    A major US university located in one of the most active innovation
and commercialisation hubs

●    A leading Chilean University - two-year engagement

●    A Singapore University recognised for its design centric research

 

Further discussions with Academic and other non-corporate research
organisations are ongoing.

 

Market Engagement

 

In addition, the Company has launched a new webinar series, GenIP Innovation
Exchange, to showcase how leading academic institutions embed GenIP's tools
into their commercialisation workflows. The first session, scheduled for 27
January, will feature King Abdullah University of Science and Technology
(KAUST).

 

 

Melissa Cruz, CEO of GenIP, commented:

 

"We are encouraged by the strong year-on-year growth in the business and the
increasing use of our higher-value portfolio products. Positive feedback from
existing clients is leading to inbound referrals, and our partnerships are
already generating corporate orders, expanding our corporate client base. We
are also in ongoing discussions with institutions we met through our 2025
event attendance and marketing efforts, which gives us confidence in the
opportunity ahead."

 

FY 2024 was from incorporation on 23 February 2024 to 31 December 2024

 

For further information regarding GenIP, please visit www.genip.ai
(http://www.genip.ai/) , or contact:

 

 GenIP Plc                                                                 Via Redchurch Communications

 Melissa Cruz, CEO

 Beaumont Cornish Limited (Nominated Adviser)                              Tel:  +44 (0) 20 7628 3396

 Roland Cornish / Asia Szusciak / Andrew Price

 AlbR Capital Limited (Broker)                                             Tel: +44 (0)20 7399 9427

 Colin Rowbury                                                             cr@albrcapital.com (mailto:cr@albrcapital.com)

 Jon Belliss                                                               Jb@albrcapital.com (mailto:Jb@albrcapital.com)

 Redchurch Communications (Financial PR)                                   genip@weareredchurch.com (mailto:genip@weareredchurch.com)

 John Casey

The information communicated within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulations (EU) No
596/2014 which is part of UK law by virtue of the European Union (Withdrawal)
Act 2018.

 

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated
Adviser and is authorised and regulated by the FCA. Beaumont Cornish's
responsibilities as the Company's Nominated Adviser, including a
responsibility to advise and guide the Company on its responsibilities under
the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed
solely to the London Stock Exchange. Beaumont Cornish is not acting for and
will not be responsible to any other persons for providing protections
afforded to customers of Beaumont Cornish nor for advising them in relation to
the proposed arrangements described in this announcement or any matter
referred to in it.

 

Notes to Editors

 

About GenIP

 

GenIP is a next-generation business      at the intersection of
generative AI and innovation strategy. We empower corporates, venture funds,
and research institutions to evaluate, commercialise, and scale breakthrough
technologies. By combining proprietary GenAI algorithms with expert human
analysis, GenIP delivers decision-grade insights and talent solutions that
accelerate innovation outcomes.

 

Service Offerings

 

GenIP operates through two synergistic service lines:

 

 

 Service                               Description                                                                   Value Proposition
 Invention Intelligence Product Suite  AI-powered market intelligence reports assessing the commercial potential of  Enables faster, evidence-based decisions on R&D prioritisation,
                                       emerging technologies                                                         investment, and IP strategy
 Talent and Executive Search Services  Executive search platform using machine learning and NLP to match             De-risks scaling by aligning technical vision with proven executive capability
                                       innovation-driven organisations with commercialisation-ready leadership

 

Together, these services form a unified GenAI-enabled platform for innovation
triage and execution.

 

Vision & Strategy

 

GenIP aims to become the global leader in generative AI analytics for
innovation commercialisation. Our strategy is anchored in three growth
pillars:

 

●    Organic Expansion

Scale Invention Evaluator and Recruitment Services through targeted outreach
to corporates, VCs, and research institutions, supported by strategic
marketing and digital engagement.

●    Service Deepening

Enhance functionality and margin by expanding GenAI capabilities within both
service lines-unlocking new use cases and customer segments.

●    Strategic Acquisitions

Pursue bolt-on acquisitions of complementary GenAI services with validated
market traction to broaden our offering and accelerate growth.

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking
statements. When used in this announcement, the words "may", "would", "could",
"will", "intend", "plan", "anticipate", "believe", "seek", "propose",
"estimate", "expect", and similar expressions, as they relate to the Company,
are intended to identify forward-looking statements. These statements include,
but are not limited to, statements regarding intentions, beliefs or current
expectations concerning, among other things, the Company's results of
operations, financial position, liquidity, prospects, growth, strategies and
expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future
events and are subject to certain risks, uncertainties and assumptions. Many
factors could cause the Company's actual results, performance or achievements
to materially differ from those described in this announcement Should one or
more of these risks or uncertainties materialise, or should assumptions
underlying forward-looking statements prove incorrect, actual results may
differ materially from those described in this announcement as "intended",
"planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any
hyperlinks accessible from the Company's website are not incorporated by
reference into, and do not form part of, this announcement and investors
should not rely on them.

-ENDS-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDQZLFFQFLBBBK



            Copyright 2019 Regulatory News Service, all rights reserved